AbstractAn efficient generic static headspace gas chromatography (HSGC) method was developed, optimized and validated for the routine determination of several residual solvents (RS) in drug substance, using a strategy with two sets of calibration. Dimethylsulfoxide (DMSO) was selected as the sample diluent and internal standards were used to minimize signal variations due to the preparative step. A gas chromatograph from Agilent Model 6890 equipped with flame ionization detector (FID) and a DB-624 (30m×0.53mm i.d., 3.00µm film thickness) column was used. The inlet split ratio was 5:1. The influencing factors in the chromatographic separation of the analytes were determined through a fractional factorial experimental design. Significant vari...
Residual solvents in pharmaceutical samples are monitored using gas chromatography with head space. ...
Objectives: A simple and sensitive gas chromatographic method was developed and validat...
Objective : Arterolane maleate is an antimalarial drug currently under Phase III clinical evaluation...
An efficient generic static headspace gas chromatography (HSGC) method was developed, optimized and...
AbstractAn efficient generic static headspace gas chromatography (HSGC) method was developed, optimi...
The main objective was to develop and validate a method to assaying simultaneously nine residual sol...
The purpose of the present work was to find optimum conditions of headspace gas chromatography (HS-G...
The main effects of six experimental factors on the efficiency of HS (headspace) extraction in heads...
Objective: Residual solvents are undesirable components present in Active Pharmaceutical Ingredients...
Objectives: Palonosetron is an antidote to 5-HT3 in the prevention and treatment of chemotherapy-ind...
A simple and sensitive static head space gas chromatographic (SH-GC) method equipped with FID has b...
The determination of residual solvents in drug substances is the mandatory requirement by various he...
This thesis describes the development of separation methods of known residual solvents from pharmace...
Residual solvents in pharmaceutical samples are monitored using gas chromatography with head space. ...
The chromatographic conditions were optimized using headspace gas chromatography, and a simple and r...
Residual solvents in pharmaceutical samples are monitored using gas chromatography with head space. ...
Objectives: A simple and sensitive gas chromatographic method was developed and validat...
Objective : Arterolane maleate is an antimalarial drug currently under Phase III clinical evaluation...
An efficient generic static headspace gas chromatography (HSGC) method was developed, optimized and...
AbstractAn efficient generic static headspace gas chromatography (HSGC) method was developed, optimi...
The main objective was to develop and validate a method to assaying simultaneously nine residual sol...
The purpose of the present work was to find optimum conditions of headspace gas chromatography (HS-G...
The main effects of six experimental factors on the efficiency of HS (headspace) extraction in heads...
Objective: Residual solvents are undesirable components present in Active Pharmaceutical Ingredients...
Objectives: Palonosetron is an antidote to 5-HT3 in the prevention and treatment of chemotherapy-ind...
A simple and sensitive static head space gas chromatographic (SH-GC) method equipped with FID has b...
The determination of residual solvents in drug substances is the mandatory requirement by various he...
This thesis describes the development of separation methods of known residual solvents from pharmace...
Residual solvents in pharmaceutical samples are monitored using gas chromatography with head space. ...
The chromatographic conditions were optimized using headspace gas chromatography, and a simple and r...
Residual solvents in pharmaceutical samples are monitored using gas chromatography with head space. ...
Objectives: A simple and sensitive gas chromatographic method was developed and validat...
Objective : Arterolane maleate is an antimalarial drug currently under Phase III clinical evaluation...